Skip to main content

Drug Interactions between encorafenib and mobocertinib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

encorafenib mobocertinib

Applies to: encorafenib and mobocertinib

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with strong or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations and anti-cancer activity of mobocertinib, which is primarily metabolized by the isoenzyme. Based on drug interaction studies using model-informed approaches, coadministration of mobocertinib with multiple doses of rifampin (a strong CYP450 3A4 inducer) is predicted to decrease the steady-state combined molar AUC (systemic exposure) of mobocertinib and its active metabolites by 92%, while coadministration with multiple doses of efavirenz (a moderate CYP450 3A4 inducer) is predicted to decrease this value by 58%.

MANAGEMENT: Coadministration of mobocertinib with strong or moderate CYP450 3A4 inducers should be avoided.

Drug and food interactions

Major

encorafenib food

Applies to: encorafenib

You should preferably avoid consumption of grapefruit and grapefruit juice while taking encorafenib. Grapefruit and grapefruit juice can significantly increase the blood levels of encorafenib. This may increase the risk of serious side effects such as bleeding complications, eye and vision problems, liver problems, irregular heart rhythm, and development of new skin cancers. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Major

mobocertinib food

Applies to: mobocertinib

You should avoid consumption of grapefruit and grapefruit juice during treatment with mobocertinib. Grapefruit juice can increase the blood levels of mobocertinib. This may increase the risk of side effects such as diarrhea, nausea, vomiting, rash, fatigue, musculoskeletal pain, mouth sores and inflammation, heart failure, and rare but potentially serious and life-threatening irregular heart rhythm disorders. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer